EC-0652

EC-0652 is an investigational diagnostic radiopharmaceutical developed as a companion imaging agent for the therapeutic candidate EC1169. It is designed to target prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells, enabling non-invasive whole-body characterization of PSMA expression in real time. The compound incorporates technetium Tc99m as a radionuclide, allowing for single-photon emission computed tomography (SPECT) imaging. Its primary use has been in identifying patients with metastatic castration-resistant prostate cancer (mCRPC) who may benefit from PSMA-targeted therapies such as EC1169. The mechanism of action involves binding to the PSMA receptor and emitting ionizing radiation detectable by nuclear medicine techniques[1][2][4][5][6][7][9].

Other names

Technetium Tc99m PSMA targeting-agentsPSMA-targeted imaging agent (prostate cancer)Prostate-specific membrane antigen targeted imaging agent